Global Cluster Of Differentiation (CD) Antigen Cancer Therapy Market - Industry Trends and Forecast to 2029

Global Cluster Of Differentiation (CD) Antigen Cancer Therapy Market, By Drugs (Ofatumumab, Rituximab, Ocrelizumab, Obinutuzumab, Others), Route of Administration (Intravenous, Subcutaneous, Others),  End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) - Industry Trends and Forecast to 2029

Market Analysis and Insights

Cluster of differentiation (CD) antigens are a group of special molecules on the surface of the cells. The cluster of differentiation (CD) antigen cancer therapy is a medical approach that is used for the identification and investigation of cell surface and are used to classify white blood cells.         

• The cluster of differentiation (CD) antigen cancer therapy are supportive and aim to reduce the severity of the symptoms. Data Bridge Market Research analyses that the cluster of differentiation (CD) antigen cancer therapy market will grow at a CAGR of 8.40% during the forecast period of 2022 to 2029.

Cluster Of Differentiation (CD) Antigen Cancer Therapy Market Dynamics

Drivers

• Cancer

Growing prevalence of cancer globally is one of the major factors fostering growth in the demand for cluster of differentiation (CD) antigen cancer therapy. More than 10 million patients die of cancer every year. However, atleast one third of the common cancers are curable. And this has created a wide scope of growth of the cluster of differentiation (CD) antigen cancer therapy market.       

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of cluster of differentiation (CD) antigen cancer therapy market is the rising healthcare expenditure which helps in improving its infrastructure. Growth and expansion of healthcare industry especially in the developing economies would invite the use and application of new and advanced medial technologies, equipment and drugs. This will directly increase the demand for cluster of differentiation (CD) antigen cancer therapy.

• Research and development activities

Growing number of strategic collaboration between public and private market players is inducing growth in the number of research and development activities on daily basis. These research and development proficiencies are being conducted in the area of novel drugs and medical technologies which will propel the demand for cluster of differentiation (CD) antigen cancer therapy.

Furthermore, unhealthy lifestyle of individuals, rising initiatives by public and private organizations to spread awareness and well-organized distribution network of leading manufacturers are the factors that will expand the market growth rate. Other factors such as increase in the demand for effective therapies, on-going clinical trial conducted by pharmaceuticals companies to develop newer therapy and rising adoption rate for early diagnostic procedures will positively impact the market's growth rate.

Opportunities

Rise in the level of personal disposable income and growing awareness in the developing economies pertaining to the availability of treatment options will further create lucrative market growth opportunities. Rising medical tourism globally, rising approval of newer cluster of differentiation (CD)directed monoclonal antibodies, increasing stress issues among people and high potential of growth in the untapped market will create enough market growth opportunities.  

Restraints/Challenges

However, high costs associated with research and development proficiencies will emerge as one of the biggest restraints for the market. Dearth of awareness and required infrastructural facilities in the underdeveloped and backward economies, adverse effects of anti-cancer drug therapy and unfavourable conditions arising due to COVID-19 outbreak will further derail the market growth rate. Slow rate of approval for drugs and inhibitors and increasing cases of patent expiry will also challenge the market growth rate. 

This cluster of differentiation (CD) antigen cancer therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on cluster of differentiation (CD) antigen cancer therapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

According to the World Health Organization, cancer is one of the leading causes of death worldwide  and there has been a rise in the global cancer burden of 19.3 million cases.

The cluster of differentiation (CD) antigen cancer therapy market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Cluster Of Differentiation (CD) Antigen Cancer Therapy Market

COVID-19 has led to denting the cluster of differentiation (CD) antigen cancer therapy market growth rate. The consumer demand has subsequently reduced owing to delay in diagnosis, drug shortages, and other factors. Further, supply chain disruptions owing to restrictions and lockdown have hampered to effectivity of online and offline distribution channels. However, it must be noted that the post pandemic phase will generate lucrative growth opportunities for the cluster of differentiation (CD) antigen cancer therapy market.  

Recent Development

• Merck Co. & Inc., received the United States Food & Drug Administration approval in November 2020, for Keytruda in combination with chemotherapy in the treatment of triple-negative breast cancer.

Global Cluster Of Differentiation (CD) Antigen Cancer Therapy Market Scope

The cluster of differentiation (CD) antigen cancer therapy market is segmented on the basis of drugs, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drugs

• Ofatumumab
• Rituximab
• Ocrelizumab
• Obinutuzumab
• Others

The drug segment for cluster of differentiation (CD) antigen cancer therapy market includes ofatumumab, rituximab, ocrelizumab, obinutuzumab and others.

Route of Administration

• Intravenous
• Subcutaneous
• Others

Route of administration segment of cluster of differentiation (CD) antigen cancer therapy market is segmented into intravenous, subcutaneous and others.

End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

On the basis of end-users, the cluster of differentiation (CD) antigen cancer therapy market is segmented into hospitals, specialty clinics and others.

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

On the basis of distribution channel, the cluster of differentiation (CD) antigen cancer therapy market has been bifurcated into hospital pharmacy, online pharmacy and retail pharmacy.

Pipeline Analysis

The University of Sussex identified the role of lemur tyrosine kinase 3 (LMTK3) in the cell proliferation in breast cancer in November 2020 and since then are planning to advance the research toward developing LMTK3 specific drugs. Novartis AG, Pfizer Inc., F. Hoffmann-La Roche, Eisai Co. Ltd, and Merck & Co. Inc. and others are the involved in the development of potential drugs for the improvement of treatment of cancer.

Cluster Of Differentiation (CD) Antigen Cancer Therapy Market Regional Analysis/Insights

The cluster of differentiation (CD) antigen cancer therapy market is analysed and market size insights and trends are provided by country, drugs, route of administration, end-users and distribution channel as referenced above.

The countries covered in the cluster of differentiation (CD) antigen cancer therapy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the cluster of differentiation (CD) antigen cancer therapy market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of major key players, well-developed healthcare infrastructure in this region and rising cases of nervous system disorders. Asia-Pacific on the other hand is projected to exhibit the highest growth rate during the forecast period due to the increasing patient pool and growing government support.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Cluster Of Differentiation (CD) Antigen Cancer Therapy Market Share Analysis

The cluster of differentiation (CD) antigen cancer therapy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cluster of differentiation (CD) antigen cancer therapy market.

Some of the major players operating in the cluster of differentiation (CD) antigen cancer therapy market are Pfizer Inc., AstraZeneca, ANI Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd, Zydus Cadila, Cipla Inc., Amneal Pharmaceuticals LLC, Glenmark Pharmaceuticals Limited, Fresenius Kabi AG, Mayne Pharma Group Limited, Mylan N.V., Novartis AG., Vintage Labs, Dr. Reddy’s Laboratories Ltd, Jiangsu Hengrui Medicine Co., Ltd, Novo Nordisk A/S, Otsuka America Pharmaceutical, Inc., and WOCKHARDT among others.

SKU-52386